There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity:
wherein R
1
, R
2
, R
3
, R
4
, and R
5
in the formula (1) each has the same meaning as defined in the specification.
IMIDAZOTHIAZOLE DERIVATIVES HAVING PROLINE RING STRUCTURE
申请人:Uoto Kouichi
公开号:US20110301176A1
公开(公告)日:2011-12-08
There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity.
Imidazothiazole Derivatives Having Proline Ring Structure
申请人:DAIICHI SANKYO COMPANY, LIMITED
公开号:US20130172362A1
公开(公告)日:2013-07-04
Compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and that exhibit anti-tumor activity are provided. Compounds provided by the present disclosure include imidazothiazole derivatives that inhibit interaction between Mdm2 protein and p53 protein and exhibit anti-tumor activity.
Imidazothiazole derivatives having proline ring structure
申请人:Uoto Kouichi
公开号:US08404691B2
公开(公告)日:2013-03-26
There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity.
There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity:
wherein R1, R2, R3, R4, and R5 in the formula (1) each has the same meaning as defined in the specification.